{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T09:10:13Z","timestamp":1717924213929},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,6,2]],"date-time":"2015-06-02T00:00:00Z","timestamp":1433203200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s11864-015-0351-7","type":"journal-article","created":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T06:01:38Z","timestamp":1433138498000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Follicular Lymphoma: First-Line Treatment Without Chemotherapy for Follicular Lymphoma"],"prefix":"10.1007","volume":"16","author":[{"given":"Patrick M.","family":"Reagan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,6,2]]},"reference":[{"key":"351_CR1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001. Blood. 2006;107:265\u201376.","journal-title":"Blood"},{"key":"351_CR2","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","volume":"27","author":"JW Friedberg","year":"2009","unstructured":"Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009;27:1202\u20138.","journal-title":"J Clin Oncol"},{"key":"351_CR3","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","volume":"23","author":"RI Fisher","year":"2005","unstructured":"Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23:8447\u201352.","journal-title":"J Clin Oncol"},{"key":"351_CR4","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","volume":"24","author":"Q Liu","year":"2006","unstructured":"Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006;24:1582\u20139.","journal-title":"J Clin Oncol"},{"key":"351_CR5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","volume":"122","author":"D Tan","year":"2013","unstructured":"Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and relative survival in follicular grade 1\u20132 lymphoma during 4 decades: the Stanford University experience. Blood. 2013;122:981\u20137. This study provides evidence of improving survival of patients with follicular lymphoma.","journal-title":"Blood"},{"key":"351_CR6","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/leu.2014.251","volume":"29","author":"HR Junlen","year":"2015","unstructured":"Junlen HR, Peterson S, Kimby E, et al. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study. Leukemia. 2015;29:668\u201376. This study provides evidence of improving survival of patients with follicular lymphoma.","journal-title":"Leukemia"},{"key":"351_CR7","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, et al. Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203\u201310.","journal-title":"Lancet"},{"key":"351_CR8","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","volume":"105","author":"A Smith","year":"2011","unstructured":"Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105:1684\u201392.","journal-title":"Br J Cancer"},{"key":"351_CR9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bjh.12562","volume":"163","author":"MH Shirley","year":"2013","unstructured":"Shirley MH, Sayeed S, Barnes I, Finlayson A, Ali R. Incidence of haematological malignancies by ethnic group in England, 2001\u20137. Br J Haematol. 2013;163:465\u201377.","journal-title":"Br J Haematol"},{"key":"351_CR10","unstructured":"Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. <br \/>. Fourth ed. Geneva, Switzerland: World Health Organization; 2008."},{"key":"351_CR11","first-page":"2975","volume":"43","author":"CD Bloomfield","year":"1983","unstructured":"Bloomfield CD, Arthur DC, Frizzera G, et al. Nonrandom chromosome abnormalities in lymphoma. Cancer Res. 1983;43:2975\u201384.","journal-title":"Cancer Res"},{"key":"351_CR12","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1172\/JCI113235","volume":"80","author":"WB Graninger","year":"1987","unstructured":"Graninger WB, Seto M, Boutain B, et al. Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells. JClin Invest. 1987;80:1512.","journal-title":"JClin Invest"},{"key":"351_CR13","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1056\/NEJM198806233182502","volume":"318","author":"BY Ngan","year":"1988","unstructured":"Ngan BY, Chen-Levy Z, Weiss LM, et al. Expression in non-Hodgkin\u2019s lymphoma of the bcl-2 protein associated with the t(8;14) chromosomal translocation. N Engl J Med. 1988;318:1638.","journal-title":"N Engl J Med"},{"key":"351_CR14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ajh.10437","volume":"74","author":"S Tomita","year":"2003","unstructured":"Tomita S, Kojima M, Imura J, et al. Extranodal diffuse follicular center lymphoma mimicking mantle cell lymphoma of the intestine. Am J Hematol. 2003;74:287\u20139.","journal-title":"Am J Hematol"},{"key":"351_CR15","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-2559.2004.01804.x","volume":"44","author":"JR Goodlad","year":"2004","unstructured":"Goodlad JR, MacPherson S, Jackson R, et al. Scotland and Newcastle Lymphoma Group. Extranodal follicular lymphoma: a clinicopathological and genetic analysis of 15 cases arising at non-cutaneous extranodal sites. Histopathology. 2004;44:268\u201376.","journal-title":"Histopathology"},{"key":"351_CR16","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1365-2141.2011.08596.x","volume":"153","author":"C Fernandez de Larrea","year":"2011","unstructured":"Fernandez de Larrea C, Martinez-Pozo A, Mercadal S, et al. Initial features and outcome of cutaneous and non-cutaneous primary extranodal follicular lymphoma. Br J Haematol. 2011;153:334\u201340.","journal-title":"Br J Haematol"},{"key":"351_CR17","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368. Updated consensus staging and response assessment recommendations for Hodgkin and non-Hodgkin lymphoma.","journal-title":"J Clin Oncol"},{"key":"351_CR18","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","volume":"351","author":"SS Dave","year":"2004","unstructured":"Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351:2159\u201369.","journal-title":"N Engl J Med"},{"key":"351_CR19","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1182\/blood-2006-09-046391","volume":"109","author":"E Sakhinia","year":"2007","unstructured":"Sakhinia E, Glennie C, Hoyland JA, et al. Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling. Blood. 2007;109:3922\u20138.","journal-title":"Blood"},{"key":"351_CR20","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1182\/blood-2007-10-115915","volume":"111","author":"RJ Byers","year":"2008","unstructured":"Byers RJ, Sakhinia E, Joseph P, et al. Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. Blood. 2008;111:4764\u201370.","journal-title":"Blood"},{"key":"351_CR21","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2012.44.2137","volume":"31","author":"S Kiaii","year":"2013","unstructured":"Kiaii S, Clear AJ, Ramsay AG, et al. Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. J Clin Oncol. 2013;31:2654\u201361.","journal-title":"J Clin Oncol"},{"key":"351_CR22","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258\u201365.","journal-title":"Blood"},{"key":"351_CR23","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555\u201362.","journal-title":"J Clin Oncol"},{"key":"351_CR24","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"P Brice","year":"1997","unstructured":"Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 1997;15:1110\u20137.","journal-title":"J Clin Oncol"},{"key":"351_CR25","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","volume":"362","author":"KM Ardeshna","year":"2003","unstructured":"Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362:516\u201322.","journal-title":"Lancet"},{"key":"351_CR26","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.2010.33.4474","volume":"30","author":"P Solal-Celigny","year":"2012","unstructured":"Solal-Celigny P, Bellei M, Marcheselli L, et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol. 2012;30:3848\u201353.","journal-title":"J Clin Oncol"},{"key":"351_CR27","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/bjc.1994.213","volume":"69","author":"B Vaughan Hudson","year":"1994","unstructured":"Vaughan Hudson B, Vaughan Hudson G, MacLennan KA, et al. Clinical stage 1 non-Hodgkin\u2019s lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer. 1994;69:1088\u201393.","journal-title":"Br J Cancer"},{"key":"351_CR28","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","volume":"14","author":"MP Mac Manus","year":"1996","unstructured":"Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996;14:1282\u201390.","journal-title":"J Clin Oncol"},{"key":"351_CR29","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0360-3016(01)01747-3","volume":"51","author":"RB Wilder","year":"2001","unstructured":"Wilder RB, Jones D, Tucker SL, et al. Long-term results with radiotherapy for stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys. 2001;51:1219\u201327.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"351_CR30","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1002\/cncr.25117","volume":"116","author":"BA Campbell","year":"2010","unstructured":"Campbell BA, Voss N, Woods R, et al. Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer. 2010;116:3797\u2013806.","journal-title":"Cancer"},{"key":"351_CR31","first-page":"103-717X-7-103","volume":"7","author":"M Guckenberger","year":"2012","unstructured":"Guckenberger M, Alexandrow N, Flentje M. Radiotherapy alone for stage I-III low grade follicular lymphoma: long-term outcome and comparison of extended field and total nodal irradiation. Radiat Oncol. 2012;7:103-717X-7-103.","journal-title":"Radiat Oncol"},{"key":"351_CR32","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.25149","volume":"116","author":"TJ Pugh","year":"2010","unstructured":"Pugh TJ, Ballonoff A, Newman F, Rabinovitch R. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a surveillance, epidemiology, and end results database analysis. Cancer. 2010;116:3843\u201351.","journal-title":"Cancer"},{"key":"351_CR33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","volume":"100","author":"L Lowry","year":"2011","unstructured":"Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100:86\u201392.","journal-title":"Radiother Oncol"},{"key":"351_CR34","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1200\/JCO.2011.40.6546","volume":"30","author":"JW Friedberg","year":"2012","unstructured":"Friedberg JW, Byrtek M, Link BK, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol. 2012;30:3368\u201375.","journal-title":"J Clin Oncol"},{"key":"351_CR35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/0003-4819-90-1-10","volume":"90","author":"CS Portlock","year":"1979","unstructured":"Portlock CS, Rosenberg SA. No initial therapy for stage III and IV non-Hodgkin\u2019s lymphomas of favorable histologic types. Ann Intern Med. 1979;90:10\u20133.","journal-title":"Ann Intern Med"},{"key":"351_CR36","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","volume":"311","author":"SJ Horning","year":"1984","unstructured":"Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin\u2019s lymphomas. N Engl J Med. 1984;311:1471\u20135.","journal-title":"N Engl J Med"},{"key":"351_CR37","first-page":"11","volume":"25","author":"RC Young","year":"1988","unstructured":"Young RC, Longo DL, Glatstein E, et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol. 1988;25:11\u20136.","journal-title":"Semin Hematol"},{"key":"351_CR38","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","volume":"15","author":"KM Ardeshna","year":"2014","unstructured":"Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15:424\u201335. This is a large study which randomized patients to observation, rituximab induction and rituximab induction with maintenance rituximab for 2 years. While no overall survival benefit was noted, maintenance rituximab delayed time to chemotherapy and had a positive impact on quality of live assessments.","journal-title":"Lancet Oncol"},{"key":"351_CR39","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","volume":"15","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin\u2019s lymphoma. J Clin Oncol. 1997;15:3266\u201374.","journal-title":"J Clin Oncol"},{"key":"351_CR40","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1200\/JCO.2013.52.2631","volume":"32","author":"A Salar","year":"2014","unstructured":"Salar A, Avivi I, Bittner B, et al. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study. J Clin Oncol. 2014;32:1782\u201391. Randomized study comparing subcutaneous rituximab to standard intravenous rituximab.","journal-title":"J Clin Oncol"},{"key":"351_CR41","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","volume":"103","author":"M Ghielmini","year":"2004","unstructured":"Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004;103:4416\u201323.","journal-title":"Blood"},{"key":"351_CR42","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2005.12.052","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin\u2019s lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol. 2005;23:1103\u20138.","journal-title":"J Clin Oncol"},{"key":"351_CR43","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","volume":"23","author":"JD Hainsworth","year":"2005","unstructured":"Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin\u2019s lymphoma\u2013a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005;23:1088\u201395.","journal-title":"J Clin Oncol"},{"key":"351_CR44","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","volume":"32","author":"BS Kahl","year":"2014","unstructured":"Kahl BS, Hong F, Williams ME, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol. 2014;32:3096\u2013102. Randomized study comparing maintenance rituximab to retreatment at progression strategies. Similar clinical outcomes noted with much less resource consumption in the retreatment arm.","journal-title":"J Clin Oncol"},{"key":"351_CR45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050064","volume":"5","author":"M Winiarska","year":"2008","unstructured":"Winiarska M, Bil J, Wilczek E, et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med. 2008;5, e64.","journal-title":"PLoS Med"},{"key":"351_CR46","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.2009.23.4245","volume":"28","author":"GS Nowakowski","year":"2010","unstructured":"Nowakowski GS, Maurer MJ, Habermann TM, et al. Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol. 2010;28:412\u20137.","journal-title":"J Clin Oncol"},{"key":"351_CR47","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00277-010-0926-0","volume":"89","author":"P Samaras","year":"2010","unstructured":"Samaras P, Heider H, Haile SR, et al. Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. Ann Hematol. 2010;89:783\u20137.","journal-title":"Ann Hematol"},{"key":"351_CR48","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1182\/blood-2014-01-547869","volume":"123","author":"HE Kohrt","year":"2014","unstructured":"Kohrt HE, Sagiv-Barfi I, Rafiq S, et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood. 2014;123:1957\u201360.","journal-title":"Blood"},{"key":"351_CR49","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3324\/haematol.2014.107011","volume":"100","author":"F Roit Da","year":"2015","unstructured":"Da Roit F, Engelberts PJ, Taylor RP, et al. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica. 2015;100:77\u201386.","journal-title":"Haematologica"},{"key":"351_CR50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","volume":"97","author":"P Colombat","year":"2001","unstructured":"Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101\u20136.","journal-title":"Blood"},{"key":"351_CR51","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1093\/annonc\/mds177","volume":"23","author":"P Colombat","year":"2012","unstructured":"Colombat P, Brousse N, Salles G, et al. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. Ann Oncol. 2012;23:2380\u20135.","journal-title":"Ann Oncol"},{"key":"351_CR52","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","volume":"28","author":"G Martinelli","year":"2010","unstructured":"Martinelli G, Schmitz SF, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98. J Clin Oncol. 2010;28:4480\u20134.","journal-title":"J Clin Oncol"},{"key":"351_CR53","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/ejh.12264","volume":"92","author":"HM Blommestein","year":"2014","unstructured":"Blommestein HM, Issa DE, Pompen M, et al. Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study. Eur J Haematol. 2014;92:398\u2013406.","journal-title":"Eur J Haematol"},{"key":"351_CR54","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jval.2014.12.017","volume":"18","author":"Q Chen","year":"2015","unstructured":"Chen Q, Ayer T, Nastoupil LJ, et al. Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma. Value Health. 2015;18:189\u201397.","journal-title":"Value Health"},{"key":"351_CR55","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2014.57.6801","volume":"33","author":"LI Wagner","year":"2015","unstructured":"Wagner LI, Zhao F, Hong F, et al. Anxiety and health-related quality of life among patients with low-tumor burden non-hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). J Clin Oncol. 2015;33:740\u20138. Analyzes quality of life outcomes between retreatment and maintenance rituximab strategies.","journal-title":"J Clin Oncol"},{"key":"351_CR56","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","volume":"352","author":"MS Kaminski","year":"2005","unstructured":"Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441\u20139.","journal-title":"N Engl J Med"},{"key":"351_CR57","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.2011.41.1553","volume":"31","author":"CW Scholz","year":"2013","unstructured":"Scholz CW, Pinto A, Linkesch W, et al. (90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol. 2013;31:308\u201313.","journal-title":"J Clin Oncol"},{"key":"351_CR58","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/bjh.12695","volume":"164","author":"A Ibatici","year":"2014","unstructured":"Ibatici A, Pica GM, Nati S, et al. Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study. Br J Haematol. 2014;164:710\u20136.","journal-title":"Br J Haematol"},{"key":"351_CR59","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/JCO.2013.50.3110","volume":"32","author":"TM Illidge","year":"2014","unstructured":"Illidge TM, Mayes S, Pettengell R, et al. Fractionated (90)Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF\/BNLI criteria. J Clin Oncol. 2014;32:212\u20138.","journal-title":"J Clin Oncol"},{"key":"351_CR60","first-page":"1","volume":"19","author":"AD McQuillan","year":"2014","unstructured":"McQuillan AD, Macdonald WB, Turner JH. Phase II study of first-line I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic F-fluorodeoxyglucose positron emission tomography. Leuk Lymphoma. 2014;19:1\u20137.","journal-title":"Leuk Lymphoma"},{"key":"351_CR61","doi-asserted-by":"crossref","unstructured":"Kaminski MS, Tuck M, Estes J, et al. Tositumomab and Iodine I-131 tositumomab for previously untreated, advanced-stage, follicular lymphoma: median 10 year follow-up results. Blood. 2009;114","DOI":"10.1182\/blood.V114.22.3759.3759"},{"key":"351_CR62","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","volume":"27","author":"TE Witzig","year":"2009","unstructured":"Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin\u2019s Lymphoma. J Clin Oncol. 2009;27:5404\u20139.","journal-title":"J Clin Oncol"},{"key":"351_CR63","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","volume":"140","author":"N Reddy","year":"2008","unstructured":"Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2008;140:36\u201345.","journal-title":"Br J Haematol"},{"key":"351_CR64","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","volume":"14","author":"L Wu","year":"2008","unstructured":"Wu L, Adams M, Carter T, et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008;14:4650\u20137.","journal-title":"Clin Cancer Res"},{"key":"351_CR65","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.21468","volume":"84","author":"L Zhang","year":"2009","unstructured":"Zhang L, Qian Z, Cai Z, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol. 2009;84:553\u20139.","journal-title":"Am J Hematol"},{"key":"351_CR66","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","volume":"15","author":"NH Fowler","year":"2014","unstructured":"Fowler NH, Davis RE, Rawal S, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014;15:1311\u20138. Phase 2 study evaluating the regimen of lenalidomide and rituximab in untreated patients with indolent lymphoma.","journal-title":"Lancet Oncol"},{"key":"351_CR67","doi-asserted-by":"crossref","unstructured":"Martin P, Jung SH, Johnson JL, et al. CALGB(Alliance) 50803: a phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. J Clin Oncol. 2014;32","DOI":"10.1200\/jco.2014.32.15_suppl.8521"},{"key":"351_CR68","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008\u201318.","journal-title":"N Engl J Med"},{"key":"351_CR69","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol. 2013;31:88\u201394.","journal-title":"J Clin Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-015-0351-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-015-0351-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-015-0351-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T08:42:09Z","timestamp":1717922529000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-015-0351-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,2]]},"references-count":69,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["351"],"URL":"https:\/\/doi.org\/10.1007\/s11864-015-0351-7","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,2]]},"article-number":"32"}}